$8.13
3.33% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation

Myriad Genetics, Inc. Classifications & Recommendation:

Buy
47%
Hold
29%
Sell
24%

Myriad Genetics, Inc. Price Target

Target Price $16.85
Price $8.13
Potential
Number of Estimates 17
17 Analysts have issued a price target Myriad Genetics, Inc. 2026 . The average Myriad Genetics, Inc. target price is $16.85. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 8 Analysts recommend Myriad Genetics, Inc. to buy, 5 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Myriad Genetics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 837.60 846.26
11.21% 1.03%
EBITDA Margin -3.10% 3.19%
67.25% 202.77%
Net Margin -15.37% -6.93%
60.13% 54.91%

17 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is

$846m
Unlock
. This is
1.03% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$856m 2.22%
Unlock
, the lowest is
$820m 2.10%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $838m 11.21%
2025
$846m 1.03%
Unlock
2026
$917m 8.38%
Unlock
2027
$985m 7.36%
Unlock
2028
$1.0b 5.73%
Unlock
2029
$1.1b 4.51%
Unlock

13 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is

$27.0m
Unlock
. This is
195.36% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$32.0m 213.07%
Unlock
, the lowest is
$17.0m 160.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-26.0m 63.59%
2025
$27.0m 203.79%
Unlock
2026
$52.7m 95.22%
Unlock
2027
$83.3m 58.06%
Unlock
2028
$119m 42.83%
Unlock

EBITDA Margin

2024 -3.10% 67.25%
2025
3.19% 202.77%
Unlock
2026
5.74% 79.94%
Unlock
2027
8.46% 47.39%
Unlock
2028
11.42% 34.99%
Unlock

11 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is

$-58.6m
Unlock
. This is
54.15% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$8.2m 106.43%
Unlock
, the lowest is
$-116m 9.29%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-129m 55.66%
2025
$-58.6m 54.47%
Unlock
2026
$-35.2m 39.94%
Unlock
2027
$-13.1m 62.73%
Unlock
2028
$-11.4m 13.03%
Unlock
2029
$4.6m 140.05%
Unlock

Net Margin

2024 -15.37% 60.13%
2025
-6.93% 54.91%
Unlock
2026
-3.84% 44.59%
Unlock
2027
-1.33% 65.36%
Unlock
2028
-1.10% 17.29%
Unlock
2029
0.42% 138.18%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.41 -0.64
55.66% 54.61%
P/E negative
EV/Sales 0.91

11 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is

$-0.64
Unlock
. This is
54.29% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.09 106.43%
Unlock
, the lowest is
$-1.27 9.29%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.41 55.66%
2025
$-0.64 54.61%
Unlock
2026
$-0.39 39.06%
Unlock
2027
$-0.14 64.10%
Unlock
2028
$-0.13 7.14%
Unlock
2029
$0.05 138.46%
Unlock

P/E ratio

Current -5.79 12.93%
2025
-12.66 118.65%
Unlock
2026
-21.08 66.51%
Unlock
2027
-56.56 168.31%
Unlock
2028
-65.04 14.99%
Unlock
2029
162.60 350.00%
Unlock

Based on analysts' sales estimates for 2025, the Myriad Genetics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.92 64.06%
2025
0.91 0.89%
Unlock
2026
0.84 7.73%
Unlock
2027
0.78 6.86%
Unlock
2028
0.74 5.42%
Unlock
2029
0.71 4.30%
Unlock

P/S ratio

Current 0.89 65.16%
2025
0.88 1.03%
Unlock
2026
0.81 7.74%
Unlock
2027
0.75 6.86%
Unlock
2028
0.71 5.41%
Unlock
2029
0.68 4.32%
Unlock

Current Myriad Genetics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Scotiabank
Locked
Locked
Locked Apr 01 2025
Piper Sandler
Locked
Locked
Locked Mar 12 2025
Piper Sandler
Locked
Locked
Locked Mar 04 2025
B of A Securities
Locked
Locked
Locked Mar 03 2025
Raymond James
Locked
Locked
Locked Feb 25 2025
UBS
Locked
Locked
Locked Feb 25 2025
Craig-Hallum
Locked
Locked
Locked Feb 12 2025
Analyst Rating Date
Locked
Scotiabank:
Locked
Locked
Apr 01 2025
Locked
Piper Sandler:
Locked
Locked
Mar 12 2025
Locked
Piper Sandler:
Locked
Locked
Mar 04 2025
Locked
B of A Securities:
Locked
Locked
Mar 03 2025
Locked
Raymond James:
Locked
Locked
Feb 25 2025
Locked
UBS:
Locked
Locked
Feb 25 2025
Locked
Craig-Hallum:
Locked
Locked
Feb 12 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today